S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
NASDAQ:NBIX

Neurocrine Biosciences - NBIX Price Target & Analyst Ratings

$108.25
-0.13 (-0.12%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$108.03
$109.52
50-Day Range
$107.99
$127.06
52-Week Range
$73.13
$129.29
Volume
490,039 shs
Average Volume
784,476 shs
Market Capitalization
$10.41 billion
P/E Ratio
189.92
Dividend Yield
N/A
Price Target
$122.24

Neurocrine Biosciences Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 16 Analyst Ratings

Consensus Analyst Price Target

$122.24
12.92% Upside
High Prediction$150.00
Average Prediction$122.24
Low Prediction$94.00
TypeCurrent
1/28/22 to 1/28/23
1 Month Ago
12/29/21 to 12/29/22
3 Months Ago
10/30/21 to 10/30/22
1 Year Ago
1/28/21 to 1/28/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
9 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$122.24$122.24$115.06$114.73
Predicted Upside12.92% Upside9.92% Upside21.60% Upside29.94% Upside
Get Neurocrine Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.


NBIX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NBIX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Neurocrine Biosciences Stock vs. The Competition

TypeNeurocrine BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.56
2.64
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside12.92% Upside1,055.96% Upside9.97% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/3/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$125.00 ➝ $135.00+8.85%
11/3/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$138.00 ➝ $143.00+14.68%
11/2/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$105.00 ➝ $116.00-2.85%
11/2/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$78.00 ➝ $101.00-15.38%
11/2/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$102.00 ➝ $120.00+0.54%
11/2/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$110.00 ➝ $120.00+0.54%
11/2/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform$101.00 ➝ $117.00-1.98%
11/2/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$127.00 ➝ $132.00+10.59%
11/2/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$125.00 ➝ $150.00+25.67%
11/2/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$91.00 ➝ $103.00-13.71%
11/2/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$100.00 ➝ $115.00-3.65%
10/24/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$114.00 ➝ $128.00+15.47%
10/11/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$136.00+27.29%
8/5/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$110.00 ➝ $113.00+17.79%
4/28/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/3/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Biren Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold$94.00+5.98%
2/24/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$115.00+31.99%
2/14/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Fein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$140.00+62.58%
12/8/2021Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$140.00 ➝ $154.00+87.23%
9/22/2021Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
1/26/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
11/10/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$149.00 ➝ $138.00+57.03%
11/10/2020Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$105.00 ➝ $90.00-2.81%
9/30/2020Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
2/14/2020Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Paul Matteis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$127.00+21.76%
(Data available from 1/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NBIX Price Target - Frequently Asked Questions

What is Neurocrine Biosciences's consensus rating and price target?

According to the issued ratings of 16 analysts in the last year, the consensus rating for Neurocrine Biosciences stock is Moderate Buy based on the current 7 hold ratings and 9 buy ratings for NBIX. The average twelve-month price prediction for Neurocrine Biosciences is $122.24 with a high price target of $150.00 and a low price target of $94.00. Learn more on NBIX's analyst rating history.

Do Wall Street analysts like Neurocrine Biosciences more than its competitors?

Analysts like Neurocrine Biosciences less than other Medical companies. The consensus rating for Neurocrine Biosciences is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how NBIX compares to other companies.

Does Neurocrine Biosciences's stock price have much upside?

According to analysts, Neurocrine Biosciences's stock has a predicted upside of 9.92% based on their 12-month price targets.

What analysts cover Neurocrine Biosciences?

Stock Ratings Reports and Tools

This page (NASDAQ:NBIX) was last updated on 1/28/2023 by MarketBeat.com Staff